Tags

Type your tag names separated by a space and hit enter

Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
Pharmacol Rep. 2009 Jan-Feb; 61(1):13-21.PR

Abstract

The endocannabinoid system is a crucial player in the inflammatory processes underlying atherosclerosis. Recently, basic research studies and animal models have strongly supported the role of the endocannabinoid system not only in the regulation of classical cardiovascular risk factors (including lipid profile and glucose homeostasis), but also in the activation of immune cells and inflammatory mediators. Clinical trials investigating treatment with rimonabant (a selective antagonist of the cannabinoid type 1 receptor) have suggested a beneficial effect of this drug in the management of obesity. Further studies are needed to explore a possible use for rimonabant in treating type 2 diabetes and acute and chronic cardiovascular disease. Despite the slight increase in adverse events (mainly psychiatric), which has led to the recent withdrawal of rimonabant from the market, CB(1) receptor antagonism might represent a very promising therapeutic strategy to reduce the cardiovascular risk. In the present review, we focused on the most important experimental investigations into the role of the endocannabinoid system in atherosclerosis and cardiovascular risk.

Authors+Show Affiliations

Division of Cardiology, Foundation for Medical Researches, University Hospital, Geneva, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19307689

Citation

Mach, François, et al. "Effect of Blockage of the Endocannabinoid System By CB(1) Antagonism On Cardiovascular Risk." Pharmacological Reports : PR, vol. 61, no. 1, 2009, pp. 13-21.
Mach F, Montecucco F, Steffens S. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. Pharmacol Rep. 2009;61(1):13-21.
Mach, F., Montecucco, F., & Steffens, S. (2009). Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. Pharmacological Reports : PR, 61(1), 13-21.
Mach F, Montecucco F, Steffens S. Effect of Blockage of the Endocannabinoid System By CB(1) Antagonism On Cardiovascular Risk. Pharmacol Rep. 2009 Jan-Feb;61(1):13-21. PubMed PMID: 19307689.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. AU - Mach,François, AU - Montecucco,Fabrizio, AU - Steffens,Sabine, PY - 2008/09/25/received PY - 2009/01/28/revised PY - 2009/3/25/entrez PY - 2009/3/25/pubmed PY - 2009/7/1/medline SP - 13 EP - 21 JF - Pharmacological reports : PR JO - Pharmacol Rep VL - 61 IS - 1 N2 - The endocannabinoid system is a crucial player in the inflammatory processes underlying atherosclerosis. Recently, basic research studies and animal models have strongly supported the role of the endocannabinoid system not only in the regulation of classical cardiovascular risk factors (including lipid profile and glucose homeostasis), but also in the activation of immune cells and inflammatory mediators. Clinical trials investigating treatment with rimonabant (a selective antagonist of the cannabinoid type 1 receptor) have suggested a beneficial effect of this drug in the management of obesity. Further studies are needed to explore a possible use for rimonabant in treating type 2 diabetes and acute and chronic cardiovascular disease. Despite the slight increase in adverse events (mainly psychiatric), which has led to the recent withdrawal of rimonabant from the market, CB(1) receptor antagonism might represent a very promising therapeutic strategy to reduce the cardiovascular risk. In the present review, we focused on the most important experimental investigations into the role of the endocannabinoid system in atherosclerosis and cardiovascular risk. SN - 1734-1140 UR - https://www.unboundmedicine.com/medline/citation/19307689/Effect_of_blockage_of_the_endocannabinoid_system_by_CB_1__antagonism_on_cardiovascular_risk_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1734-1140(09)70003-9 DB - PRIME DP - Unbound Medicine ER -